Funding Acknowledgements: Topic: Pharmacology and Pharmacotherapy -Other Background: The optimal treatment for microvascular angina (MVA) remains to be established. Purpose and methods: The aim of study was to assess the effects of trimetazidine (TMZ) in patients with MVA. 90 symptomatic patients with MVA were randomized into 2 groups: the "TMZ" received standard medical therapy (b/calcium channel blockers, statins, antiplatelets, long-acting nitrates) and TMZ 35 mg bid for 3 months (M3), the control group (CG) received only the standard therapy. Treadmill test (TT), response in myocardial blood flow (MBF) and reserve of the endothelium-dependent vasodilation (REDV) to cold pressor testing (CPT) in the left anterior descending artery (LAD), left circumflex artery (LCx), and right coronary artery (RCA) assessed by 13N-ammonia positron emission tomography (PET), measurement of the reactive hyperemia index (RHI) by peripheral arterial tonometry, assessments of quality of life (QOL) and pain with the Seattle Angina Questionnaire (SAQ), measurement of circulating endothelial cells (CECs), serum endothelin-1 level (ET-1), and total antioxidant status (TOS) were carried out at baseline (M0) and after M3 of treatment. Results: Both groups were similar at baseline. At M3, 26.7% of patients in the TMZ group and 83.3% of patients in the CG (P<0.05) had a positive TT. TMZ treatment was associated with improvements in all SAQ scores. At the M3 follow-up, 40% of patients in the TMZ group were angina-free, 33.3% had class I angina, and 26.7% had class II angina (P<0.05), while there were no significant changes in angina class in the CG. Response of MBF and REDV to CPT significantly improved in the TMZ group in all arteries compared with baseline and with the CG at M3. TMZ group M0 vs M3 (LAD MBFa CPT 86.2AE29.7; REDVb -1.8 [-20.5; 17.6] Funding Acknowledgements: Topic: Lipids Purpose: The aim of this study was to evaluate the effect of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab/alirozumab in patients with coronary heart disease (CHD) and inappropriate lowering of LDL cholesterol plus statin/ezetimibe therapy. Methods: Twelve patients (m: 9, age 58.3AE9.7 years) with coronary heart disease (3-vessel disease (VD): n=8, 2-VD: n=2, 1-VD= n=2; first CHD manifestation at the age of 47.4AE6.6 years; multiple intervention before apheresis: PCI: 9 pats, CABG: 6 pats, PCI+CABG: 3 pat) underwent regular (once a week) lipid apheresis at our Center. We applied 140 mg of the PCSK9 inhibitor evolocumab subcutaneously at a 2-week interval after lipid apheresis under continuation of the maximally tolerated statin/ezetimibe therapy. Prior to lipid apheresis, mean total cholesterol was 241AE44 mg/dl, LDL cholesterol 158AE30 mg/dl and mean Lp(a) (5 pats) 83AE8 mg/dl. The mean number of lipid apheresis procedures in these patients was 493 (range 34 1025) with an at least 60% LDL cholesterol and Lp(a) reduction. Results: Only 2 weeks after the first administration of evolocumab under continued weekly lipid apheresis and statin/ezetimibe therapy, total cholesterol and LDL cholesterol were markedly reduced. This effect was still present after 4, 24 and 52 weeks (Table) . The influence on Lp(a) reduction however was markedly lower (Table) . Within 2 weeks, evolocumab was able to reduce total cholesterol by 34.6% and LDL cholesterol by 48.9%, while Lp(a) reduction only amounted to 19.68%. This effect was not significantly higher after 24 and 52 weeks (p>0.5). After 8 weeks the interapheresis interval could be prolonged from 1 to 2 weeks in 4 pats. In 2 pats apheresis could be discontinued. Conclusion: After one year an effective reduction of LDL cholesterol by PCSK9 inhibitor administration was evident despite a prolonged apheresis interval or an interrupted apheresis therapy in a small collective. As expected the impact on Lp(a) concentration was only of minor importance. The influence of the added PCSK9 inhibitor under continuing apheresis on the progression of coronary heart disease has to analysed in the near future. Nine homozygote, two compound heterozygote, and 82 heterozygote FH patients and 85 healthy subjects were prospectively studied. Longitudinal and circumferential strain measurements and conventional echocardiography findings were obtained. Results LV ejection fractions were similar for all (homozygote, heterozygote, and control) groups. The LV average longitudinal strain (aLS) and average circumferential strain (aCS) levels were significantly reduced in the homozygote and heterozygote groups when compared with the controls (for aLS, p = 0.008 (<0.001); for aCS, p = <0.001). A significant inverse correlation was found between LDL-C levels and LS (p < 0.001, r = 0.728) and CS (p < 0.001, r = 0.642) for all FH patients. Conclusions This study demonstrates the potential of using systolic strain values obtained using 2D STE for determining lipotoxicity in the myocardium owing to hypercholesterolemia. Our study found that cardiac functions of homozygote patients who had the highest cholesterol levels 
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Funding Acknowledgements: Topic: Lipids Purpose: The aim of this study was to evaluate the effect of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab/alirozumab in patients with coronary heart disease (CHD) and inappropriate lowering of LDL cholesterol plus statin/ezetimibe therapy. Methods: Twelve patients (m: 9, age 58.3AE9.7 years) with coronary heart disease (3-vessel disease (VD): n=8, 2-VD: n=2, 1-VD= n=2; first CHD manifestation at the age of 47.4AE6.6 years; multiple intervention before apheresis: PCI: 9 pats, CABG: 6 pats, PCI+CABG: 3 pat) underwent regular (once a week) lipid apheresis at our Center. We applied 140 mg of the PCSK9 inhibitor evolocumab subcutaneously at a 2-week interval after lipid apheresis under continuation of the maximally tolerated statin/ezetimibe therapy. Prior to lipid apheresis, mean total cholesterol was 241AE44 mg/dl, LDL cholesterol 158AE30 mg/dl and mean Lp(a) (5 pats) 83AE8 mg/dl. The mean number of lipid apheresis procedures in these patients was 493 (range 34 1025) with an at least 60% LDL cholesterol and Lp(a) reduction. Results: Only 2 weeks after the first administration of evolocumab under continued weekly lipid apheresis and statin/ezetimibe therapy, total cholesterol and LDL cholesterol were markedly reduced. This effect was still present after 4, 24 and 52 weeks (Table) . The influence on Lp(a) reduction however was markedly lower (Table) . Within 2 weeks, evolocumab was able to reduce total cholesterol by 34.6% and LDL cholesterol by 48.9%, while Lp(a) reduction only amounted to 19.68%. This effect was not significantly higher after 24 and 52 weeks (p>0.5). After 8 weeks the interapheresis interval could be prolonged from 1 to 2 weeks in 4 pats. In 2 pats apheresis could be discontinued. Conclusion: After one year an effective reduction of LDL cholesterol by PCSK9 inhibitor administration was evident despite a prolonged apheresis interval or an interrupted apheresis therapy in a small collective. As expected the impact on Lp(a) concentration was only of minor importance. The influence of the added PCSK9 inhibitor under continuing apheresis on the progression of coronary heart disease has to analysed in the near future. Objective: To compare associations of behavioural and related factors for incident subarachnoid and intracerebral haemorrhage and ischaemic stroke. Methods: 712,433 Million Women Study participants without prior stroke, heart disease or cancer reported behavioural and related factors at baseline (1999) (2000) (2001) (2002) (2003) (2004) and were followed by record linkage to national hospital admission and death databases. Cox regression yielded adjusted relative risks (RRs) by type of stroke, and meta-analyses were conducted of relevant published prospective studies. Results: After 12.9 (SD 2.6) years follow-up, 8128 women had an incident ischaemic stroke, 2032 intracerebral haemorrhage and 1536 subarachnoid haemorrhage. In women with diabetes, risk of ischaemic stroke was substantially increased (RR=2.01; 95% CI 1.84-2.20), intracerebral haemorrhage slightly increased (1.31; 1.04-1.65) but subarachnoid haemorrhage reduced (0.43; 0.26-0.69; heterogeneity by stroke type, p<0.0001). Current smokers were at an increased risk of all three stroke types, although greater for subarachnoid haemorrhage (15+ cigarettes/day vs never smoker, RR=4.75; 4.13-5.46) than for intracerebral haemorrhage (2.28; 1.93-2.70) or ischaemic stroke (2.50; 2.29-2.72); heterogeneity p<0.0001. Hypertension was also associated with increased risk of all stroke types, and particularly of ischaemic stroke; obesity was associated with an increased risk of ischaemic stroke and a decreased risk of haemorrhagic stroke (heterogeneity for both, p<0.0001). Meta-analyses confirmed substantial heterogeneity in these associations across the three types of stroke. Conclusion: Classic risk factors for stroke have considerably different effects on the three main pathological types of stroke. These findings reinforce the importance of addressing a range of cardiovascular risk factors in reducing the incidence of the three main types of stroke. Background: Population studies on coronary heart disease (CHD) have historically focused on myocardial infarction (MI) and total CHD. There is limited understanding of trends in various CHD subgroups and how they compare between countries. Purpose: To compare trends in hospitalisation rates for CHD and its subgroups between England and Australia from 1996 to 2013 using electronic health data. Methods: All hospitalisations for CHD in 35-84 yr olds in England and Australia from 1996-2013 were identified and stratified by subgroup using ICD codes (acute: MI, unstable angina; non-acute: stable angina, other CHD). Regional linked data from the Oxford Record Linkage Study (ORLS) and Western Australia (WA) were used to account for the effect of transfers and coronary procedure admissions on trends. Annual age-standardised rates were calculated and standardised to the 2013 European Population age distribution. Age-adjusted trends were estimated from Poisson regression models separately for 1996-2003 and 2004-2013 to account for non-linear trends.
Results: There were 6.5 million CHD hospital admissions in England, and 2.5 million in Australia from 1996-2013 (men 67% both countries). Total CHD hospitalisation rates were higher in Australia than England in 1996 (men 3049 vs 1812; women 1435 vs 768 per 100,000 respectively). Rates of total CHD declined consistently in Australia from 1996 onwards. Rates increased by 2.3%/yr in England from 1996-2003, and then declined from 2004 on, with rates in 2013 similar to 1996 levels in men and women. The proportion of acute admissions declined in England (48% in 1996 England (48% in -2003 England (48% in , 44% in 2004 England (48% in -2013 but was unchanged in Australia (56%). From 1996-2003, rates increased in England across all CHD subgroups except stable angina while only MI rates increased in Australia. From 2004 on, trends were more consistently downward in all subgroups in both countries. Age-specific trends generally reflected overall trends in each subgroup except for MI rates in younger women in 2004-2013, where the trend was upward (England +1.4%/yr, 95% CI +1.0, +1.7; Australia +1.9%/yr, 95% CI +1.4, +2.4). Analysis of the linked regional data indicated that the national increases in MI rates in 1996-2003 were associated with an increasing rate of transfers in both countries. Increasing MI rates were also seen in WA from 2004-2013 for men and women. An increasing proportion of admissions for other CHD were for coronary procedures (mainly angiogram) in ORLS (71% in 1996; 84% in 2013) and WA (88% in 1996; 91% in 2013).
Conclusion: CHD hospitalisation rates have declined in both countries, although only since 2004 in England, implying more recent improvements in management of CHD and risk factors. Non-acute CHD hospitalisations are a major component of CHD burden, requiring better understanding of the management and outcomes of these patients. The presence of upward trends in MI rates in younger women in both countries requires further investigation. Funding Acknowledgements: Topic: Diabetes and the Heart Introduction: The associated mortality and morbidity rate from complications of type 2 diabetes (T2DM) and the 'metabolic syndrome' continues to soar. Low carbohydrate (LC) dietary approaches have been shown in studies to be beneficial. However, widespread uptake of the LC diet remains slow and clinician confidence in the available evidence is variable. Purpose: To evaluate the efficacy and safety of a LC diet in a cohort of metabolic syndrome and T2DM patients in a large UK general practice by assessment of effects on weight, serum parameters of metabolic syndrome, and diabetic control. Methods: Over a period of 4 years, a LC diet was opportunistically recommended to patients demonstrating ! 2 features of metabolic syndrome including; obesity (BMI > 30), abnormal gamma GT (GGT), hypertension, glucose intolerance or T2DM. Patients agreed to sharing of anonymised data and close follow-up consisting of monthly weight and bi-monthly blood tests. Baseline measurements included; weight, blood pressure, HbA1c, liver, renal, thyroid function and fasting lipids. Results: One hundred and thirty-five participants were included, mean age 60 (range 53 to 83), 57% female. At baseline, 65 were diabetic and 102 had pre-diabetes/diabetes. See table for main results. Profound, statistically significant changes were seen across all main parameters including weight; BMI; GGT; HbA1c; cholesterol; triglycerides; HDL; BP. Full diabetes 'remission' whilst off all medication was achieved in 17 (26%) of T2DM patients. There were no adverse events reported. Conclusions: Implementation of a LC diet in metabolic syndrome and type 2 diabetes appears to be safe, and results in significant weight loss, improved liver function tests and lipid markers, with significant reductions in HbA1c and blood pressure. 'Remission' of type 2
Abstract No: 91. HbA1c in diabetic patients on a LC diet diabetes off medication also appears possible in some cases. Randomised studies are urgently needed for further validation and assessment of hard cardiac and vascular endpoints.
Patient characteristics
Baseline Material and methods: Our double-blind study included 58 patients with AP, noninvasively confirmed myocardial ischemia and a normal coronary angiogram. The effect of once daily 20 mg atorvastatin (A) was compared with placebo (P) for 6 months. Endothelial function was evaluated by flow-mediated dilation (FMD) of the brachial artery, and microcirculation by peripheral arterial tonometry (EndoPAT) measuring the reactive hyperemia index (RHI), indicating microcirculatory endothelial function, and the augmentation index (AI), an indicator of arterial stiffness. The impact of AP on the quality of life was monitored using the Seattle Angina Questionnaire (SAQ). Results: Brachial artery endothelial dysfunction was found in 91.4% of patients at study entry, and subnormal RHI in 41%. Group A showed an improvement of FMD compared with group P, both at 3 and 6 months (+120.8% vs. 21.2%, and +70.8% vs. 1.9%, respectively, p < 0.001). No difference was detected in the RHI. Rate-normalized AI showed an improvement (114.49% group A vs. 30.77% group P, p = 0.077), although the differences between the groups were not significant. According to the SAQ, an improvement was found in almost all observed variables with the exception of the issue of quality of life (QoL), where patients in both groups assessed their QoL at the control study visits as poorer compared with baseline. Conclusions: Moderate dose atorvastatin therapy improves endothelial function of large conduit arteries in patients with AP and a normal coronary angiogram, which probably reflects positive effects on coronary artery endothelial function. No effect was found with vascular effects at the level of the peripheral microcirculation. Funding Acknowledgements: Topic: Obesity Background The incidence of obesity has reached epidemic levels and so far, the only treatment with a relatively longstanding effect in morbidly obese patients is bariatric surgery (BS). While weight loss is very rapid after BS, patients not only lose fat mass (FM) but also important fat free mass (FFM). Moreover, in the absence of lifestyle changes, patients tend to regain weight in the longer term. With only a small number of heterogeneous studies with contradictory results, the current evidence regarding the effects of exercise training therapy on body composition and physical fitness after BS remains inconclusive. Purpose Our aim was therefore to perform a systematic review and meta-analysis in order to document the effects of exercise therapy on body composition, exercise capacity and cardiovascular risk factors in patients who underwent BS. Methods We conducted a literature search in 4 electronic databases to identify controlled trials evaluating the effect of exercise training in patients following BS, published up to July 2017. The primary outcome was body composition; secondary outcomes included exercise capacity and cardiovascular risk factors. Random effects models were used and subgroup analysis was performed according to the timing of the exercise program. Results Nine studies with 384 patients (43.1AE9.2 years, 87.8% female) could be included. Overall, exercise therapy resulted in a significantly better improvement in body composition (body weight: -2.57 kg (-4.42 to -0.73) p=0.006; fat mass: -2.26 kg (-3.52 to -1.01) p<0.001; waist circumference -4.09 cm (-7.26 to -0.92) p=0.01) and a larger increase in exercise tolerance (3.21 ml/kg/min (0.99 to 5.43) p=0.01). Results were more pronounced in the subgroup of patients that initiated an exercise program three months after BS, except with regard to conservation of FFM (1.47 kg (-0.40 to 3.34) p=0.12) for which an early exercise intervention might be warranted. Resting heart rate decreased significantly more after exercise training (-5.89 bpm (-9.12 to -2.66) p<0.001), while no significant effects were found for blood pressure, fasting insulin, glucose and blood lipids. Conclusion Exercise training in a later stage after BS results in a larger reduction in body weight, FM and waist circumference compared to standard care. When initiated shortly after BS, FFM seems to be better preserved. Larger studies investigating structured exercise programs including both aerobic endurance as well as resistance training are needed in order to find the most optimal training characteristics for post-bariatric patients.
